Roxanne Nelson, BSN, RN

Treatment for hepatitis C is associated with a reduction in cardiovascular events.

CAP guidelines recommend transitioning to an oral beta-lactam or fluoroquinolone regimen when patients are clinically stable, but because of common adverse effects, stewardship efforts are frequently focused on reducing initial fluoroquinolone use for CAP therapy.